AltimmuneALT
About: Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Employees: 59
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
39% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $8.53M
24% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
3% less funds holding
Funds holding: 172 [Q2] → 166 (-6) [Q3]
6.04% less ownership
Funds ownership: 61.59% [Q2] → 55.54% (-6.04%) [Q3]
17% less capital invested
Capital invested by funds: $290M [Q2] → $242M (-$48.5M) [Q3]
21% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 28
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Patrick Trucchio 36% 1-year accuracy 51 / 142 met price target | 32%upside $12 | Buy Reiterated | 14 Nov 2024 |
UBS Eliana Merle 38% 1-year accuracy 5 / 13 met price target | 185%upside $26 | Buy Initiated | 12 Nov 2024 |
Financial journalist opinion
Based on 11 articles about ALT published over the past 30 days